Metformina + Vildagliptina Pharmakern

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Pharmakern, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients, often in combination with other antidiabetic agents.

GNH USA supplies Metformina + Vildagliptina Pharmakern as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Vildagliptina Pharmakern is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder.

Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels. Adjunct therapy in patients inadequately controlled on metformin alone: provides additional glucose‑lowering effect. Combination therapy with insulin: helps reduce the required insulin dose while maintaining target glucose levels.

The medication may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Headache: mild tension‑type headache. - Dizziness: sensation of light‑headedness, especially after initiating therapy.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain. - Anaphylaxis: rare systemic allergic response. - Hepatic failure: rare severe liver injury.

Before prescribing Metformina + Vildagliptina Pharmakern, clinicians should evaluate patient‑specific risk factors.

Renal impairment: assess kidney function and adjust dose as needed. Hepatic impairment: monitor liver enzymes and avoid use in severe liver disease. Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. Pregnancy and lactation: use only if potential benefit outweighs risk. Alcohol consumption: limit intake to reduce risk of metabolic acidosis. Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture.

Metformina + Vildagliptina Pharmakern may interact with several concomitant medicines.

Major Interactions (Avoid): - Insulin secretagogues (e.g., sulfonylureas): increased risk of hypoglycemia. - Iodinated contrast agents: potential for acute renal dysfunction with metformin. - Cimetidine: may raise metformin plasma concentrations. - Strong CYP3A4 inhibitors: can elevate vildagliptin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes.